Pharmaceuticals

The Leqvio Market Is Evolving Due To The Rise In Demand For Personalized Medicine Fueling The Growth Of The Due To Increased Adoption Of Genomic-Driven Therapies

May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Leqvio Market Between 2026 And 2030?

Growth witnessed during the historic period resulted from the rising incidence of hyperlipidemia, breakthroughs in RNA interference technology, the ongoing expansion of cardiovascular specialty clinics, an increasing understanding of LDL cholesterol management, and enhancements in injectable drug delivery systems.

The anticipated expansion during the forecast timeframe stems from the wider acceptance of new RNA-based treatments, a heightened attention to mitigating cardiovascular risks, the development of therapies requiring less frequent administration, increased funding directed towards cardiometabolic studies, and a greater need for long-lasting cholesterol-reducing methods.

Key developments expected over the forecast horizon encompass a rise in the use of siRNA-based therapies to reduce lipids, a growing preference for cardiovascular therapies with extended effects, an intensifying emphasis on proactive heart care strategies, the broadening of sophisticated RNA production techniques, and a stronger focus on improving patient compliance with treatments.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

What Key Factors Are Affecting The Leqvio Market Demand?

The increasing number of older adults is anticipated to fuel the demand for leqvio in the future. This demographic comprises people generally aged 65 years and older. Significant progress in healthcare and medical technology has notably extended life expectancy, thus expanding the geriatric demographic. Leqvio helps reduce LDL cholesterol, simplifying medication routines for senior citizens. Its prolonged action diminishes cardiovascular hazards, thereby improving health results among the elderly. For example, data from January 2024, provided by the Population Reference Bureau, a Kenya-based nonprofit, indicates that the count of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Concurrently, this cohort’s proportion of the total population is forecast to increase from 17% to 23% within the same timeframe. Consequently, the expanding geriatric population is a key catalyst for the leqvio market’s expansion.

Which Segments Define The Leqvio Market Segment Structure?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

What Emerging Trends Are Seen In The Leqvio Market?

Companies operating in the leqvio market are concentrating on the development of advanced injectable prescription medicines, including those requiring Label Expansion, to improve therapeutic accessibility and facilitate early intervention. Label Expansion denotes the regulatory authorization, typically from bodies like the FDA, permitting an already approved drug to be utilized for new indications, different patient demographics, or in varied clinical environments beyond its initial approval. As an illustration, in July 2023, Novartis AG, a pharmaceutical firm based in Switzerland, obtained US Food and Drug Administration (FDA) approval for an updated label for Leqvio (inclisiran). This update enables the drug’s administration at an earlier stage for individuals with elevated LDL-C and a heightened risk of heart disease, alongside diet and statin treatment. Following two initial doses, Leqvio requires two subsequent doses annually, offering up to a 52% reduction in LDL-C and demonstrating efficacy for patients who cannot achieve their LDL-C target even with statin therapy. The updated label underscores the strong safety and efficacy data, which was further substantiated by the VictORION clinical trial program.

Who Are The Established Players Within The Leqvio Market?

Major companies operating in the leqvio market are Novartis AG

Get The Full Leqvio Market Report:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

Where Is The Leqvio Market Primarily Concentrated By Region?

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Leqvio Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

Browse Through More Reports Similar to the Global Leqvio Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795